Mesalazine in inflammatory bowel disease: a trendy topic once again?

Research output: Contribution to journalArticlepeer-review

Standard

Mesalazine in inflammatory bowel disease : a trendy topic once again? / Iacucci, Marietta; de Silva, Shanika; Ghosh, Sabrata.

In: Canadian Journal of Gastroenterology, Vol. 24, No. 2, 02.2010, p. 127-33.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Iacucci, Marietta ; de Silva, Shanika ; Ghosh, Sabrata. / Mesalazine in inflammatory bowel disease : a trendy topic once again?. In: Canadian Journal of Gastroenterology. 2010 ; Vol. 24, No. 2. pp. 127-33.

Bibtex

@article{07f71fdd2cc246869d2d0dedb6c5b111,
title = "Mesalazine in inflammatory bowel disease: a trendy topic once again?",
abstract = "5-aminosalicylic acid (5-ASA) preparations (eg, mesalazine, mesalamine) are well-established preparations used in the management of inflammatory bowel disease. These drugs are most useful for the treatment of mild to moderate flares of ulcerative colitis and, especially, for maintenance of remission. Although most gastroenterologists are very familiar with these drugs, the interest in these drugs has undergone a resurgence, with new preparations offering convenience and high dosage, while preserving their customary safety. New dosage regimens are likely to become standard practice in the near future. There is also considerable interest in chemoprevention of colorectal cancer in the context of inflammatory bowel disease, and the role of long-term maintenance therapy with 5-ASAs in achieving such chemoprevention. A mechanism of action for such chemoprevention has been provided by the agonism of the peroxisome proliferator-activated receptor-gamma by 5-ASA, which unifies its efficacy as an anti-inflammatory and chemopreventive agent. In the future, even more effective agents based on 5-ASA are expected, based on more powerful agonism of peroxisome proliferator-activated receptor-gamma; 5-ASA preparations have become 'trendy' again.",
keywords = "Anti-Inflammatory Agents, Non-Steroidal, Colitis, Ulcerative, Colorectal Neoplasms, Crohn Disease, Humans, Mesalamine, PPAR gamma, Remission Induction, Tablets, Journal Article, Review",
author = "Marietta Iacucci and {de Silva}, Shanika and Sabrata Ghosh",
year = "2010",
month = feb,
language = "English",
volume = "24",
pages = "127--33",
journal = "Canadian Journal of Gastroenterology",
issn = "0835-7900",
publisher = "Pulsus",
number = "2",

}

RIS

TY - JOUR

T1 - Mesalazine in inflammatory bowel disease

T2 - a trendy topic once again?

AU - Iacucci, Marietta

AU - de Silva, Shanika

AU - Ghosh, Sabrata

PY - 2010/2

Y1 - 2010/2

N2 - 5-aminosalicylic acid (5-ASA) preparations (eg, mesalazine, mesalamine) are well-established preparations used in the management of inflammatory bowel disease. These drugs are most useful for the treatment of mild to moderate flares of ulcerative colitis and, especially, for maintenance of remission. Although most gastroenterologists are very familiar with these drugs, the interest in these drugs has undergone a resurgence, with new preparations offering convenience and high dosage, while preserving their customary safety. New dosage regimens are likely to become standard practice in the near future. There is also considerable interest in chemoprevention of colorectal cancer in the context of inflammatory bowel disease, and the role of long-term maintenance therapy with 5-ASAs in achieving such chemoprevention. A mechanism of action for such chemoprevention has been provided by the agonism of the peroxisome proliferator-activated receptor-gamma by 5-ASA, which unifies its efficacy as an anti-inflammatory and chemopreventive agent. In the future, even more effective agents based on 5-ASA are expected, based on more powerful agonism of peroxisome proliferator-activated receptor-gamma; 5-ASA preparations have become 'trendy' again.

AB - 5-aminosalicylic acid (5-ASA) preparations (eg, mesalazine, mesalamine) are well-established preparations used in the management of inflammatory bowel disease. These drugs are most useful for the treatment of mild to moderate flares of ulcerative colitis and, especially, for maintenance of remission. Although most gastroenterologists are very familiar with these drugs, the interest in these drugs has undergone a resurgence, with new preparations offering convenience and high dosage, while preserving their customary safety. New dosage regimens are likely to become standard practice in the near future. There is also considerable interest in chemoprevention of colorectal cancer in the context of inflammatory bowel disease, and the role of long-term maintenance therapy with 5-ASAs in achieving such chemoprevention. A mechanism of action for such chemoprevention has been provided by the agonism of the peroxisome proliferator-activated receptor-gamma by 5-ASA, which unifies its efficacy as an anti-inflammatory and chemopreventive agent. In the future, even more effective agents based on 5-ASA are expected, based on more powerful agonism of peroxisome proliferator-activated receptor-gamma; 5-ASA preparations have become 'trendy' again.

KW - Anti-Inflammatory Agents, Non-Steroidal

KW - Colitis, Ulcerative

KW - Colorectal Neoplasms

KW - Crohn Disease

KW - Humans

KW - Mesalamine

KW - PPAR gamma

KW - Remission Induction

KW - Tablets

KW - Journal Article

KW - Review

M3 - Article

C2 - 20151072

VL - 24

SP - 127

EP - 133

JO - Canadian Journal of Gastroenterology

JF - Canadian Journal of Gastroenterology

SN - 0835-7900

IS - 2

ER -